Your session is about to expire
← Back to Search
pembrolizumab for Esophageal Cancer
Study Summary
This trial is testing a new cancer treatment combination to see what effects it has on patients with esophagogastric cancer.
- Esophageal Cancer
- Stomach Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 1274 Patients • NCT02220894Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any serious risks associated with pembrolizumab treatment?
"The safety of pembrolizumab has been rated as a 2 since it is currently running Phase 2 trials with limited evidence in regards to efficacy and moderate data regarding safety."
Is there any precedent for utilizing pembrolizumab in medical research?
"Pembrolizumab was first studied at the City of Hope Comprehensive Cancer Center in 1997 and has since been a subject of 2543 trials. Currently, there are 2251 studies that have open recruitment; Middletown, New jersey serves as one major hub for these clinical investigations."
How many healthcare facilities are actively participating in this trial?
"Patients may choose from 8 distinct clinical trial sites, including Memorial Sloan Kettering Monmouth in Middletown and other locations."
What is the current number of participants in this research endeavor?
"Unfortunately, recruitment for this study has ended. It was initially announced on November 3rd 2016 and the last update was released September 19th 2022. For those seeking other trials involving esophageal neoplasms malignant there are 531 recruiting studies while 2251 clinical initiatives are actively searching for people to participate in research regarding pembrolizumab."
Is there an ongoing recruitment process for this clinical experiment?
"Unfortunately, this clinical trial has closed its doors to new patients. Initially posted on the 3rd of November 2016 and last updated 19th September 2022, it is no longer actively looking for recruits. However, there are presently 531 trials recruiting participants with esophageal neoplasms malignant and 2,251 studies that require pembrolizumab volunteers."
What medical indications is pembrolizumab designed to address?
"Pembrolizumab is regularly used for treating refractory, relapsed mediastinal large b-cell lymphoma. Additionally, it can be utilized to address many other conditions like advanced testicular cancer and inflammatory breast cancer (IBC). It has even been successful in controlling the proliferation of refractory fallopian tube carcinomas."
Share this study with friends
Copy Link
Messenger